Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: Phase ii study

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3327-3334

  Kawano, Yuko ^a   Ohyanagi, Fumiyoshi ^a   Yanagitani, Noriko ^a   Kudo, Keita ^a   Horiike, Atsushi ^a   Tanimoto, Azusa ^a   Nishizawa, Hironari ^a   Ichikawa, Atsuo ^a   Sakatani, Toshio ^a   Nakatomi, Katsumi ^a   Hagiwara, Sachiko ^a   Ninomiya, Hironori ^b   Motoi, Noriko ^b   Ishikawa, Yuichi ^b   Horai, Takeshi ^a   Nishio, Makoto ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

ALK; Cisplatin; Japanese; Non squamous NSCLC; Pemetrexed

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; FOLIC ACID; MULTIVITAMIN; PEMETREXED;

ADULT; ADVANCED CANCER; ADVANCED NON SQUAMOUS NON SMALL CELL LUNG CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RECURRENCE; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ERUPTION; FEBRILE NEUTROPENIA; FEMALE; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; JAPANESE; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; WILD TYPE;

ALK; CISPLATIN; JAPANESE; NON-SQUAMOUS NSCLC; PEMETREXED;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; GENOTYPE; GLUTAMATES; GUANINE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84883290944     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA and Johnson BE: Twenty-two years of phase III trials for patients with advanced non-small cell lung cancer: Sobering results. J Clin Oncol 19: 1734-1742, 2001.
2. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995.
3. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323, 2007.
4. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP and Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH and Eastern Cooperative Oncology G: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002.
6. Kut V, Patel JD and Argiris A: Pemetrexed: A novel antifolate agent enters clinical practice. Expert Rev Anticancer Ther 4: 511-522, 2004.
7. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L and Bunn PA Jr.: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004.
8. Kubota K, Niho S, Enatsu S, Nambu Y, Nishiwaki Y, Saijo N and Fukuoka M: Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: Review of results from an open-label randomized phase II study. J Thorac Oncol 4: 1530-1536, 2009.
9. Mitsudomi T: Advances in target therapy for lung cancer. Jpn J Clin Oncol 40: 101-106, 2010.
10. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H and Ji H: Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28: 4616-4620, 2010.
11. Camidge DR, Kono SA, Lu X, Okuyama S, Baron AE, Oton AB, Davies AM, Varella-Garcia M, Franklin W and Doebele RC: Anaplastic lymphoma kinase gene rearrangements in nonsmall cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 6: 774-780, 2011.
12. Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, Chung DH, Kim WH, Kim YT, Yang SC, Kim YW, Heo DS and Bang YJ: Anaplastic lymphoma kinase translocation: A predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 6: 1474-1480, 2011.
13. Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, Awad MM, Engelman JA, Riely GJ, Monica V, Yeap BY and Scagliotti GV: Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol 24: 59-66, 2013.
14. Wu SG, Yang CH, Yu CJ, Lee JH, Hsu YC, Chang YL, Shih JY and Yang PC: Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer 72: 333-339, 2011.
15. Syrigos KN, Vansteenkiste J, Parikh P, von Pawel J, Manegold C, Martins RG, Simms L, Sugarman KP, Visseren-Grul C and Scagliotti GV: Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatingemcitabine in advanced non-small-cell lung cancer. Ann Oncol 21: 556-561, 2010.
16. Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, Ichinose Y, Adachi S, Nambu Y, Saijo N and Fukuoka M: Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: A phase I/II study in Japanese patients. Jpn J Clin Oncol 38: 339-346, 2008.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
18. The National Cancer Institute Common Toxicity Criteria: http://ctep.cancer.gov/protocolDevelopment/electronic-applicatio ns/docs/ctcaev3.pdf.
19. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y and Mano H: KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15: 3143-3149, 2009.
20. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
21. Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R, Blatter J and Krejcy K: Front-line treatment of advanced nonsmall cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial. Ann Oncol 11: 435-440, 2000.
22. Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, Fisher B and Eisenhauer E: Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92: 595-600, 2001.
23. Yang CH, Simms L, Park K, Lee JS, Scagliotti G and Orlando M: Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: Results of an exploratory subgroup analysis of a phase III trial. J Thorac Oncol 5: 688-695, 2010.
24. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G and Peters GJ: Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in nonsmall cell lung cancer cells. Mol Pharmacol 73: 1290-1300, 2008.
25. Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, Kuwata K, Yamaguchi H, Nishio K and Nakagawa K: Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 104: 1594-1601, 2011.
26. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y and Mano H: Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature 448: 561-566, 2007.
27. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Janne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW and Shaw AT: Activity and safety of crizotinib in patients with ALK-positive non-small cell lung cancer: Updated results from a phase I study. Lancet Oncol 13: 1011-1019, 2012.
28. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD and Janne PA: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385-2394, 2013.